



News Release

TerraBioGen Announces Cornell University Study Results

Vancouver, Canada, June 8, 2012 – TerraBioGen Technologies Inc. (TSX-V: **TBG**), a developer and marketer of proprietary technologies for the production of organic-based, high-value agricultural products from organic wastes, announces the results of recent studies done by Cornell University.

The study conducted by Cornell University's Department of Horticulture was designed to assess the ability of TerraBioGen's liquid LC200 applied at several rates and intervals to reduce golf fairway turf nutrient requirements. Standard fertilizer inputs were applied at 100, 75, 50 and 25 percent of standard rates required to produce acceptable turf quality. LC200 was applied at three rates every 7, 14, 28 and 56 days. The study showed a complex interaction between turf grass and bioactive compounds in LC200, and suggests that normal fertilizer rates can be reduced as much as 75%. This study clearly indicated enhanced fertilizer use efficiency with moderate rates of LC200 applied once every two months during the growing season. Not only does this enhance economic performance, the reduction of nutrient loading into the environment offers significant protection of soil and water quality.

Blair Heffelfinger, President and CEO of TerraBioGen, said "The Cornell study reaffirms previous turf grass research indicating that treatment with TerraBioGen's LC200 will allow for a significant reduction in fertilizer input without noticeably impacting turf quality. This is a win-win situation in that it provides both economic benefits to the grounds keeper and environmental benefits to society as a whole."

About TerraBioGen Technologies

Located in North Vancouver, BC, TerraBioGen Technologies Inc. is committed to research and development to continue to improve the efficiency of its technology and the quality of its agricultural products. It is further committed to developing a world-wide marketing capability to ensure market acceptance of its products.

For more information, please contact:

Blair Heffelfinger
President & CEO

TerraBioGen Technologies Inc.
bheffelfinger@terrabiogen.com
(604) 924-1023 ext 316
(604) 924-1043 fax

Bob Nowell
CFO & Corporate Secretary

TerraBioGen Technologies Inc.
bnowell@terrabiogen.com
(604) 924-1023 ext 306
(604) 924-1043 fax

This news release contains certain statements that may be deemed "forward-looking" statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although TerraBioGen believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward looking statements are based on the beliefs, estimates and opinions of TerraBioGen's management on the date the statements are made. Except as required by law, TerraBioGen undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

THIS PRESS RELEASE, REQUIRED BY APPLICABLE CANADIAN LAWS, IS NOT FOR DISTRIBUTION TO U.S. NEWS SERVICES OR FOR DISSEMINATION IN THE UNITED STATES, AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN. THESE SECURITIES HAVE NOT BEEN

REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR TO U.S. PERSONS UNLESS REGISTERED OR EXEMPT THEREFROM.